EBR Systems, Inc. has submitted an NTAP application

EBR Systems, Inc. (ASX: EBR) has submitted the New Technology Add-On Payment application to the Centers for Medicare & Medicaid Services for its WiSE CRT System. With the FDA breakthrough device designation, EBR's WiSE CRT System meets the new technology and substantial clinical improvement requirements and sets a new standard for innovation in the industry. This pivotal step represents a significant leap forward in EBR's mission to secure US reimbursement, ensuring patients have access to this life-changing technology and driving widespread adoption in the US market. EBR is poised for FDA regulatory approval in Q1 2025, with NTAP coverage anticipated to begin in Q4 2025.

This achievement brings it closer to delivering its unparalleled technology to needy patients. The unwavering focus remains on executing its comprehensive commercialization strategy to accelerate market adoption and provide broad access throughout the US.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com